LicianPro

Vistagen Therapeutics, Inc. ·

VTGN 8-K 2026-09-24

Vistagen Therapeutics, Inc. (VTGN) 8-K dated 2026-09-24 — accession 0001628280-26-063316.

Vistagen Therapeutics, Inc. (VTGN) is a biotechnology company listed on NASDAQ.

Vistagen Therapeutics, Inc. filed a 8-K on 2026-09-24. Accession 0001628280-26-063316.

This 8-K covers: Other events (Item 8.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported VTGN revenue for 2026-03-31 was $1.3M. Net income was -$69.7M. Revenue was up 19.3% from 2024-03-31 to 2026-03-31. VTGN currently screens at market cap $28.1M.

Not investment advice. The VTGN SEC hub lists recent forms. The stock page is the research view.

Open on SEC EDGAR

These filings as JSON? API free 100/day

Lician Pro $19.99/mo or $149/yr